Page 157 - CW E-Magazine (31-12-2024)

News from Abroad

researchers working on novel approaches “Our proprietary technology stands
to treat today’s most challenging dis- at the forefront of solutions that are
eases, organoids offer critical insights driving a paradigm shift for drug
into biologic systems. We look forward discovery and development,” said
making it faster and easier for scientists Mr. Robert Vries, CEO of HUB Organoids.
to get from samples to solutions,”
said Mr. Jean-Charles Wirth, Head of The use of organoids may allow re-
Science & Lab Solutions for the life searchers to limit their reliance on animal
science business of Merck. testing by reducing stages in the R&D
culture reagents, tools and benchtop process, positively contributing to more
HUB possesses the foundational instruments for academia, biotech, and environmentally sustainable alterna-
patent portfolio on organoids and has pharma customers. HUB’s technology tives. Organoids also create opportuni-
a service offering ranging from new enables drug developers to identify and ties for genetically diverse populations
model generation to assay develop- validate potential clinical candidates in to be reflected in research. They allow
ment and high-throughput screening. a patient-relevant in vitro system, clos- scientists to better understand drug
This adds to and enhances Merck’s ing the gap between the lab and clinical interactions in patient populations that
life science business portfolio of cell trials. are underrepresented in clinical trials.

BP takes final investment decision on green hydrogen

plant in Germany

UK’s BP has taken the final invest- cesses and contribute to achieving the
ment decision (FID) for the ‘Lingen ambitious goals of the energy transition
Green Hydrogen’ project in Germany. in Germany. The renewable electricity
Supported by funding from the IPCEI required for the electrolyser is expec-
(Important Projects of Common Euro- ted to initially be supplied on the
pean Interest) programme, the plant to basis of an offshore wind power
be built as part of the 100-MW project purchase agreement (PPA).
could produce up to 11-ktpa of green
hydrogen. plant worldwide to date – and the first This investment is in line with BP’s
the company will fully own and operate. upscaling of hydrogen and CCS plans
The plant will be built next to the and is part of the five to ten investments
BP refinery in Lingen and connected The green hydrogen produced will BP plans to drive in this area globally
directly to the hydrogen core network. be offered to BP’s refineries and indus- this decade. Construction is scheduled
It is planned to be BP’s largest indus- trial customers in the region to support to start in 2025, with commissioning
trial-scale green hydrogen production the decarbonisation of production pro- expected in 2027.
Worley bags EPC contract for ExxonMobil’s hydrogen

project in Texas

Australian engineering and profes- subject to the final investment decision more than 98% of the associated CO
2
sional services company, Worley, will (FID), as well as supportive govern- emissions. A final investment deci-
provide reimbursable engineering, pro- ment policy and necessary regulatory sion (FID) is expected in 2025 with an
curement and construction (EPC) ser- permits. anticipated startup in 2029.
vices to ExxonMobil for the enabling
works, infrastructure and interconnects The Baytown facility is expected to ExxonMobil said the facility will
scope of the latter’s planned low-car- produce 28.3-million cubic metres of leverage advanced carbon CCS tech-
bon hydrogen and ammonia facility in low-carbon hydrogen daily and nearly nologies to reduce emissions associated
Baytown, Texas, USA. The contract is 1-mtpa of ammonia while capturing with hydrogen production.

Chemical Weekly December 31, 2024 157

Contents Index to Advertisers Index to Products Advertised